Economic Evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost-effective compared to an atenolol-based regimen Peter Lindgren, Martin Buxton, Thomas Kahan, et al. Updated information and services can be found at: Published online October 4, 2007 in advance of the print journal. Email alerting Receive free email alerts when new articles cite this
Suomen sivusto, jossa voit ostaa halvalla ja laadukas Viagra http://osta-apteekki.com/ toimitus kaikkialle maailmaan.
Yritti äskettäin viagra, se toimii erittäin tehokkaasti)) Ostaa Internetin kautta täällä viagra Myös ostaa levitra oikeudenkäynti, vaikutus on silmiinpistävää.
Http://www.ncbi.nlm.nih.gov/pubmed/9820260?ordinalpos=29&itool=Treatment of irritable bowel syndrome with Chinese.[JAMA. 1998] - PubMed Result A service of the U.S. National Library of Medicine 1: JAMA. 1998 Nov 11;280(18):1585-9.
ACP J Club. 1999 May-Jun;130(3):74. JAMA. 1999 Sep 15;282(11):1035-6; author reply 1036-7. Treatment of diarrhea-predominant irritable bowel syndrome JAMA. 1999 Sep 15;282(11):1035; author reply 1036-7. with traditional Chinese herbal medicine: a randomized placebo-controlled trial.
Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo- Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized
Treatment for seasonal allergic rhinitis by Chinese herbal medicine: a randomized placebo Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M.
Review Establishing evidence for Chinese medicine: a case Research Unit for Complementary Medicine, University of Western Sydney Macarthur, Campbelltown, New South Wales, Australia. email@example.com Review Tegaserod for the treatment of irritable bowel CONTEXT: Irritable bowel syndrome (IBS) is a common functional bowel disorder for which there is no reliable medical treatment. OBJECTIVE: To determine whether Chinese herbal medicine (CHM) is of any benefit in the treatment of IBS. DESIGN: Randomized, double-blind, placebo-controlled trial conducted during 1996 through 1997. SETTING: Patients were recruited through 2 teaching hospitals and 5 private Recent Activity
practices of gastroenterologists, and received CHM in 3 Chinese herbal clinics. PATIENTS: A total of 116 patients who fulfilled the Rome criteria, an established standard for diagnosis of IBS. INTERVENTION: Patients were randomly allocated to 1 of 3 treatment groups: individualized Chinese herbal formulations (n = 38), a Treatment of irritable bowel syndrome with Chinese standard Chinese herbal formulation (n = 43), or placebo (n = 35). Patients herbal medicine: a randomized controlle. received 5 capsules 3 times daily for 16 weeks and were evaluated regularly by a Establishing evidence for Chinese medicine: a case traditional Chinese herbalist and by a gastroenterologist. Patients, gastroenterologists, and herbalists were all blinded to treatment group. MAIN OUTCOME MEASURES: Change in total bowel symptom scale scores and global improvement assessed by patients and gastroenterologists and change in the Chinese herbal medicines in the treatment of ectopic degree of interference in life caused by IBS symptoms assessed by patients. RESULTS: Compared with patients in the placebo group, patients in the active treatment groups (standard and individualized CHM) had significant improvement in Chinese herbal medicine for primary dysmenorrhoea. bowel symptom scores as rated by patients (P=.03) and by gastroenterologists (P=.001), and significant global improvement as rated by patients (P=.007) and by gastroenterologists (P=.002). Patients reported that treatment significantly reduced the degree of interference with life caused by IBS symptoms (P=.03). Chinese herbal formulations individually tailored to the patient proved no more effective than standard CHM treatment. On follow-up 14 weeks after completion of treatment, only the individualized CHM treatment group maintained improvement. CONCLUSION: Chinese herbal formulations appear to offer improvement in symptoms for some patients with IBS. PMID: 9820260 [PubMed - indexed for MEDLINE] Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer http://www.ncbi.nlm.nih.gov/pubmed/9820260?ordinalpos=29&itool=EntrezSystem2. 12/02/2009
ESTATUTO SOCIAL DO INSTITUTO GEOC CAPÍTULO I DA PERSONALIDADE JURÍDICA, DENOMINAÇÃO, SEDE E FINALIDADES Artigo 1º Artigo 1º. Constituído como pessoa jurídica de direito privado, fundado em 14 de julho de 2006, o INSTITUTO GEOC é uma associação de sociedades, empresárias e não empresárias, com atividades no mercado de serviços de cobrança extrajudicial